סלובניה - סלובנית - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

gsk d.o.o., ljubljana - flutikazonpropionat - inhalacijska suspenzija pod tlakom - flutikazonpropionat 250 µg / 1 vpih - flutikazon

סלובניה - סלובנית - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

gsk d.o.o., ljubljana - flutikazonpropionat - inhalacijska suspenzija pod tlakom - flutikazonpropionat 125 µg / 1 vpih - flutikazon

סלובניה - סלובנית - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

gsk d.o.o., ljubljana - flutikazonpropionat - prašek za inhaliranje, odmerjeni - flutikazonpropionat 50 µg / 1 odmerek - flutikazon

סלובניה - סלובנית - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

gsk d.o.o., ljubljana - flutikazonpropionat - prašek za inhaliranje, odmerjeni - flutikazonpropionat 500 µg / 1 odmerek - flutikazon

סלובניה - סלובנית - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

gsk d.o.o., ljubljana - flutikazonpropionat - prašek za inhaliranje, odmerjeni - flutikazonpropionat 100 µg / 1 odmerek - flutikazon

סלובניה - סלובנית - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

gsk d.o.o., ljubljana - flutikazonpropionat - inhalacijska suspenzija pod tlakom - flutikazonpropionat 50 µg / 1 vpih - flutikazon

האיחוד האירופי - סלובנית - EMA (European Medicines Agency)

eli lilly nederland b.v. - baricitinib - artritis, revmatoidni - imunosupresivi - rheumatoid arthritisbaricitinib is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (dmards). zdravilo olumiant se lahko uporablja kot monoterapija ali v kombinaciji z metotreksatom. atopic dermatitisolumiant is indicated for the treatment of moderate to severe atopic dermatitis in adult and paediatric patients 2 years of age and older who are candidates for systemic therapy. alopecia areatabaricitinib is indicated for the treatment of severe alopecia areata in adult patients (see section 5. juvenile idiopathic arthritisbaricitinib is indicated for the treatment of active juvenile idiopathic arthritis in patients 2 years of age and older who have had an inadequate response or intolerance to one or more prior conventional synthetic or biologic dmards:- polyarticular juvenile idiopathic arthritis (polyarticular rheumatoid factor positive [rf+] or negative [rf-], extended oligoarticular),- enthesitis related arthritis, and- juvenile psoriatic arthritis. baricitinib may be used as monotherapy or in combination with methotrexate.

סלובניה - סלובנית - myHealthbox

bayer ag -

האיחוד האירופי - סלובנית - EMA (European Medicines Agency)

chiesi farmaceutici s.p.a - pegunigalsidase alfa - fabryjeva bolezen - drugi zdravljene bolezni prebavil in presnove izdelki, - elfabrio is indicated for long-term enzyme replacement therapy in adult patients with a confirmed diagnosis of fabry disease (deficiency of alpha-galactosidase).